Antibody Solutions

What Antibody Solutions does

Antibody Solutions is a privately held, fee-for-service contract research organization headquartered in Santa Clara, California, founded in 1995 and operating for 30 years. The company offers monoclonal antibody discovery services to biopharma customers through its proprietary Cellestive Discovery Platform, which executes multi-pathway B-cell screening across plasma, activated, and memory B-cell populations. Its client base exceeds 700 accounts and includes all of the top 10 global pharmaceutical companies alongside a long-tail of mid-market and emerging biopharma sponsors.

The business model is pay-as-you-go fee-for-service work in which clients retain full intellectual property rights to the antibodies and clones generated. Antibody Solutions does not take equity, milestone, or royalty positions in client programs, and the company is family-owned with no disclosed external institutional investors. Service delivery is anchored at its Santa Clara laboratory at 3033 Scott Boulevard, with project management functions supporting each engagement from kickoff through clone delivery.

The technology stack is centered on the Cellestive platform, which combines traditional hybridoma workflows with capabilities sourced through partnerships — including OmniAb (since 2012), Single Cell Technology (2017), and mAbsolve (2023) — to extend into single-cell and anti-idiotype workflows. In 2024 the company added a partnership with Leveragen and secured a $1.2 million grant from the Bill & Melinda Gates Foundation to develop malaria diagnostic antibodies, signaling selective entry into global-health reagent development alongside its commercial discovery services.

Name

Antibody Solutions

Legal name

Antibody Solutions

Website

https://antibody.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

Antibody Solutions is a Santa Clara-based fee-for-service contract research organization specializing in monoclonal antibody discovery via its proprietary Cellestive multi-pathway B-cell platform, serving 700+ biopharma clients including all top 10 global pharmaceutical companies since 1995.

Ownership category

akta.pro rank

Product category

Contract Research Organization (Antibody Discovery Services)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Custom antibody discovery
• Therapeutic antibody services
• Monoclonal antibody development
• Biopharmaceutical CRO services
• Antibody engineering platforms

Headquarters

HQ city

Santa Clara

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Fee-for-Service Antibody Discovery Services: Antibody Solutions provides custom antibody discovery and development services on a fee-for-service, pay-as-you-go basis. Clients pay for individual services or projects as needed, with pricing based on the scope and complexity of each engagement. The model allows clients to retain their IP rights.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Antibody Solutions is a contract research organization that designs and executes custom antibody discovery and development programs for biopharmaceutical companies. Its core offering is the Cellestive Discovery Platform, which interrogates plasma, activated, and memory B-cells across multiple transgenic animal platforms to generate fit-for-purpose monoclonal, polyclonal, bispecific, ADC, and single-domain antibodies for therapeutic and diagnostic use. Services are delivered on a fee-for-service, pay-as-you-go basis with clients retaining intellectual property rights.

Product overview

Antibody Solutions offers a comprehensive antibody discovery platform centered around the Cellestive Discovery Platform, which leverages multiple B-cell pathways (plasma, activated, and memory B-cells) to generate diverse therapeutic antibody candidates. The platform is supported by an integrated suite of services including antigen development, hybridoma and single B-cell screening technologies, transgenic animal platforms (OmniAb, H2L2, Singularity Sapiens Mouse), antibody manufacturing, molecular modeling, bioconjugation, and sequencing services. The company operates on a fee-for-service, pay-as-you-go model serving biopharmaceutical clients worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Cellestive: Antibody discovery platform that interrogates multiple B-cell populations (activated, memory, and plasma B-cells) for therapeutic antibody discovery

Products and services

• Cellestive Discovery Platform Proprietary antibody discovery platform that interrogates plasma, activated, and memory B-cells to generate diverse antibody repertoires for therapeutic and diagnostic applications; integrated with hybridoma screening, single B-cell analysis, FACS-based screening, and recombinant antibody expression capabilities.
• Therapeutic Antibody Discovery Custom discovery services using transgenic animals and alternative antibody modalities for developing therapeutic antibody candidates for biopharmaceutical clients.
• Critical Reagent Antibody Discovery Antibody discovery services focused on generating highly specific and reproducible critical reagents for diagnostic and research applications, including PK/PD, ADA, IHC, and Western blot assays.
• Monoclonal Antibody Discovery Monoclonal antibody generation services using hybridoma and B-cell screening technologies for therapeutic and diagnostic applications.
• Polyclonal Antibody Discovery Polyclonal antibody discovery services for research and diagnostic applications.
• Antibody Manufacturing Scale-up antibody manufacturing services for preclinical and clinical applications.
• Antigen Development Antigen design and development services supporting antibody discovery programs.
• Bioconjugation Antibody bioconjugation services for developing antibody-drug conjugates (ADCs) and other conjugated therapeutics.
• Antibody Catalog Online catalog of pre-existing antibodies available for purchase for research and diagnostic applications.
• Singularity Sapiens Mouse Platform Services CRO antibody discovery services using Leveragen's next-generation fully human single-domain antibody platform that generates heavy chain antibodies from the complete human VH repertoire.

Quantifiable outcome

• 96% of clients return with new assignments
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Leveragen, Inc.coreTechnology or Integration · 11 December 2024Antibody Solutions became an approved contract research organization (CRO) for Leveragen's Singularity Sapiens Mouse platform. This next-generation fully human single-domain antibody platform exclusively generates heavy chain antibodies through a targeted approach ensuring faithful expression of human immunoglobulin genes and eliminating interfering conventional antibodies. The partnership allows Antibody Solutions to pursue antibody discovery initiatives using Leveragen mice for clients who have licensed the proprietary platform.
• mAbsolve Ltd.coreOEM/ Whitelabel/ Licensing Partner · 4 December 2023Antibody Solutions licensed mAbsolve's STR Fc silencing technology, providing clients with easy license-free access to this best-in-class Fc silencing platform for antibody research and development. The STR technology is described as the only truly silent Fc mutation platform, improving safety and efficacy of therapeutic antibodies and Fc fusion proteins by completely silencing unwanted binding to Fc gamma receptors.
• Single Cell Technology, Inc. (SCT)coreTechnology or Integration · 1 January 2017Antibody Solutions partnered with Single Cell Technology to integrate SCT's AbTHENEUM single B-cell analysis technology with Antibody Solutions' comprehensive antibody discovery platform. This partnership enables phenotypic screening of secreted antibodies from individual B-cells and correct pairing of cognate VH and VL sequences via NGS, allowing more comprehensive interrogation of immunized animal repertoires.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• GenScript ProBio: Global CRO/CDMO offering antibody discovery, engineering, and manufacturing services. Directly comparable across therapeutic antibody discovery, hybridoma, and transgenic animal workflows, with similar biopharma buyer personas.
• AbCellera Biologics: Vancouver-based antibody discovery CRO with a proprietary single-cell screening platform. Most direct comparability: same fee-for-service discovery model serving top global pharmas, plus a therapeutic pipeline - making it the closest publicly-traded reference point for Antibody Solutions' service business.
• Sino Biological: Producer of recombinant antibody reagents and CRO services for therapeutic and diagnostic antibody discovery. Comparable hybrid business model combining catalog reagents with custom services.
• Absolute Antibody: Antibody CRO focused on antibody engineering, sequencing, and recombinant expression. Comparable mid-size fee-for-service offering for biopharma clients needing fit-for-purpose reagents and engineered formats.
• ImmunoPrecise Antibodies: Specialized CRO providing custom antibody discovery and characterization using multiple platforms including B-cell screening and transgenic animals. Closely matched size and service mix to Antibody Solutions.
• Curia (formerly LakePharma): Contract development and manufacturing organization with antibody discovery and bioconjugation services. Comparable custom antibody and ADC-adjacent service offerings for biopharma clients.

Broad incumbents

• Lonza Biologics: Global CDMO offering end-to-end biologics services including antibody discovery and manufacturing. Larger incumbent that competes for the same biopharma wallets, particularly on integrated discovery-to-manufacturing programs.
• Bio-Techne: Established life sciences tools and reagents company with antibody-related products and services. Larger portfolio player with overlap on critical reagent antibodies and assay development, but with a much broader catalog footprint.
• WuXi Biologics: Global CRDMO with antibody discovery, development, and manufacturing services. Competes for the same top-pharma discovery programs but at much larger scale, often as the integrated-services alternative to a specialized CRO like Antibody Solutions.
• Charles River Laboratories: Large CRO with comprehensive discovery and safety assessment services including antibody and biologics capabilities. Relevant as a broad incumbent buyer of outsourced discovery work from biopharma clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/antibodysol

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antibody Solutions